1. Home
  2. SRBK vs LPTX Comparison

SRBK vs LPTX Comparison

Compare SRBK & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRBK
  • LPTX
  • Stock Information
  • Founded
  • SRBK 1887
  • LPTX 2011
  • Country
  • SRBK United States
  • LPTX United States
  • Employees
  • SRBK N/A
  • LPTX N/A
  • Industry
  • SRBK
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SRBK
  • LPTX Health Care
  • Exchange
  • SRBK Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • SRBK 117.4M
  • LPTX 119.6M
  • IPO Year
  • SRBK N/A
  • LPTX N/A
  • Fundamental
  • Price
  • SRBK $14.43
  • LPTX $0.33
  • Analyst Decision
  • SRBK
  • LPTX Hold
  • Analyst Count
  • SRBK 0
  • LPTX 1
  • Target Price
  • SRBK N/A
  • LPTX N/A
  • AVG Volume (30 Days)
  • SRBK 115.0K
  • LPTX 3.3M
  • Earning Date
  • SRBK 07-25-2025
  • LPTX 08-11-2025
  • Dividend Yield
  • SRBK 1.38%
  • LPTX N/A
  • EPS Growth
  • SRBK N/A
  • LPTX N/A
  • EPS
  • SRBK N/A
  • LPTX N/A
  • Revenue
  • SRBK $27,988,000.00
  • LPTX N/A
  • Revenue This Year
  • SRBK N/A
  • LPTX N/A
  • Revenue Next Year
  • SRBK N/A
  • LPTX N/A
  • P/E Ratio
  • SRBK N/A
  • LPTX N/A
  • Revenue Growth
  • SRBK 23.80
  • LPTX N/A
  • 52 Week Low
  • SRBK $9.23
  • LPTX $0.22
  • 52 Week High
  • SRBK $14.96
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • SRBK 78.62
  • LPTX 48.69
  • Support Level
  • SRBK $13.46
  • LPTX $0.28
  • Resistance Level
  • SRBK $14.96
  • LPTX $0.36
  • Average True Range (ATR)
  • SRBK 0.25
  • LPTX 0.04
  • MACD
  • SRBK 0.12
  • LPTX 0.01
  • Stochastic Oscillator
  • SRBK 74.76
  • LPTX 39.43

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: